Voyager Therapeutics
64 Sidney Street
Cambridge
Massachusetts
02139
United States
Website: http://www.voyagertherapeutics.com/
187 articles about Voyager Therapeutics
-
Dr. Paul has been with the company for six years since its inception, initially as president of R&D,
-
MRI Interventions Recognizes FDA Clearance of Voyager’s Investigational New Drug Application for VY-AADC Allowing its Pivotal Program to Begin for Advanced Parkinson’s Disease
1/24/2018
Clearance of the IND allows Voyager to formally initiate clinical trial sites and begin screening patients for its pivotal Phase 2-3 program.
-
Voyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s Disease
1/23/2018
Pivotal Phase 2-3 program on track to dose the first patient during the second quarter of 2018.
-
Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D Day
11/17/2017
Senior executives from Voyager Therapeutics’ scientific, clinical and management team provided the highlights.
-
Voyager Therapeutics to Host R&D Day on November 16, 2017
11/13/2017
Voyager’s senior management team to highlight lead program VY-AADC for Parkinson’s disease, integration of novel capsid and delivery optimization efforts, and pipeline programs from the ALS, Huntington’s disease, Friedreich’s ataxia, anti-Tau antibody and severe chronic pain programs.
-
Voyager Therapeutics Announces Closing of Public Offering of Common Stock
11/13/2017
The aggregate net proceeds before expenses to Voyager from the offering are approximately $58.4 million, after deducting underwriting discounts and commissions.
-
Voyager Therapeutics Announces Pricing of Public Offering of Common Stock
11/8/2017
Voyager has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price.
-
Voyager Therapeutics Announces Proposed Offering of Common Stock
11/7/2017
In addition, Voyager intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.
-
Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights
11/3/2017
The company will host a conference call and webcast today at 4:30 p.m. EDT to discuss these results.
-
Shares of Voyager have fallen more than 12 percent in premarket trading after Sanofi Genzyme walked away from its $845M gene therapy treatment for Parkinson’s disease.
-
Voyager Therapeutics to Host Third Quarter 2017 Financial Results and Corporate Highlights Conference Call
10/30/2017
Management has scheduled a conference call to discuss the financial results and corporate highlights.
-
Voyager Therapeutics Announces New Data Presentations at the Congress of the European Society of ...
10/17/2017
The data includes an oral presentation related to recent results from Voyager's ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson's disease. -
On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark's Luxturna in a vote of 16 to 0.
-
Voyager Therapeutics Appoints Matthew P. Ottmer As Chief Operating Officer
9/18/2017
-
Voyager Therapeutics Touts More Gene Therapy Parkinson’s Data
9/6/2017
-
Voyager Therapeutics Reports Second Quarter 2017 Financial Results And Corporate Highlights
8/8/2017
-
Voyager Therapeutics To Host Second Quarter 2017 Financial Results And Corporate Highlights Conference Call
8/3/2017
-
Voyager Therapeutics To Host Second Quarter 2017 Financial Results And Corporate Highlights Conference Call
8/2/2017
-
Voyager Therapeutics Announces Publication From The California Institute of Technology Of A Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer To The Brain
7/17/2017
-
Voyager Therapeutics Announces Clinical Trial Update With VY-AADC01 For Advanced Parkinson’s Disease
6/26/2017